All In Biotech

Free tool

FAERS Monitor: Nor-Qd

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017060 or its brand name (Nor-Qd, Norethindrone). Reports on generic versions are filed under their own applications.

Reports

3,155

Serious

1,626

52% of reports

Hospitalization

672

Death reported

50

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea251
  • headache242
  • off label use219
  • fatigue198
  • drug ineffective193
  • pain170
  • hot flush159
  • abdominal pain151
  • vaginal haemorrhage144
  • diarrhoea141
  • vomiting133
  • arthralgia131
  • anxiety115
  • dizziness115
  • dyspnoea115

Reports by year received

View as table
YearReports
20041
20058
20063
200710
20089
200938
201050
201190
2012106
2013105
2014184
2015213
2016210
2017147
2018162
2019138
2020136
2021193
2022307
2023310
2024279
2025250
2026206

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,004 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vaginal haemorrhageSignal14422.218.92,888
hot flushSignal15914.112.11,924
abdominal painSignal1514.33.7387
anxietySignal1152.72.3122
headacheSignal2422.62.3238
nauseaSignal2512.11.9152
arthralgiaSignal1312.11.876
vomiting1331.91.656
pain1701.81.667
fatigue1981.71.558
off label use2191.71.560
dizziness1151.51.322
diarrhoea1411.51.220
dyspnoea1151.41.111
drug ineffective1931.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.